Baldwin Brothers Inc. MA lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 591 shares of the medical instruments supplier’s stock after selling 60 shares during the period. Baldwin Brothers Inc. MA’s holdings in Becton, Dickinson and were worth $115,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of BDX. Boston Financial Mangement LLC boosted its position in Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after buying an additional 5,152 shares during the last quarter. Wells Fargo & Company MN boosted its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares during the last quarter. AMG National Trust Bank boosted its position in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock worth $1,813,000 after buying an additional 401 shares during the last quarter. Fundsmith LLP boosted its position in Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Becton, Dickinson and by 7.8% in the first quarter. ProShare Advisors LLC now owns 357,269 shares of the medical instruments supplier’s stock worth $65,537,000 after buying an additional 25,809 shares during the last quarter. Institutional investors own 87.41% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) traded up 0.23% during midday trading on Thursday, hitting $198.36. The company’s stock had a trading volume of 411,329 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market cap of $45.14 billion, a price-to-earnings ratio of 57.45 and a beta of 1.05. The firm has a 50-day moving average of $200.05 and a 200 day moving average of $189.42.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.48%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Position Cut by Baldwin Brothers Inc. MA” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/31/becton-dickinson-and-company-bdx-position-cut-by-baldwin-brothers-inc-ma.html.

A number of equities analysts recently issued reports on BDX shares. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Cowen and Company restated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $195.79.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 48,605 shares of company stock worth $9,718,986 in the last 90 days. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.